Eledon Pharmaceuticals to Participate in 11th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Eledon Pharmaceuticals (NASDAQ: ELDN), a clinical stage biopharmaceutical company, announced that its CEO, David-Alexandre C. Gros, M.D., will participate in a fireside chat at the 11th Annual SVB Leerink Virtual Global Healthcare Conference on February 17 at 5:00 p.m. EST. This event focuses on innovative treatments for organ and cell transplantation, autoimmune diseases, and neurodegenerative conditions. Interested participants can register for the webcast here.

IRVINE, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the 11^th Annual SVB Leerink Virtual Global Healthcare Conference on Thursday, February 17^th at 5:00 p.m. EST.

To register in advance for the fireside chat webcast, sign up here.

Replay Link:

A replay will be accessible for 30 days following the live session on the Events page of the Investors section on the Company’s website at https://ir.eledon.com/events-and-presentations/events.

About Eledon Pharmaceuticals and tegoprubart (formerly AT-1501)

Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop potential treatments for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with ALS. The company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, Calif. For more information, please visit the company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com

FAQ

What is Eledon Pharmaceuticals participating in on February 17, 2022?

Eledon Pharmaceuticals will participate in the 11th Annual SVB Leerink Virtual Global Healthcare Conference.

What time will Eledon Pharmaceuticals' fireside chat take place?

The fireside chat will take place at 5:00 p.m. EST.

How can I register for Eledon Pharmaceuticals' fireside chat?

You can register for the webcast by signing up here.

How long will the replay of Eledon Pharmaceuticals' fireside chat be available?

The replay will be accessible for 30 days following the live session.

What is the focus of Eledon Pharmaceuticals' treatments?

Eledon Pharmaceuticals focuses on treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative diseases.